<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00663416</url>
  </required_header>
  <id_info>
    <org_study_id>NTx™-265-CP-201-IS (CA)</org_study_id>
    <nct_id>NCT00663416</nct_id>
  </id_info>
  <brief_title>REGENESIS (CA): A Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients</brief_title>
  <acronym>REGENESIS</acronym>
  <official_title>A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients (REGENESIS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stem Cell Therapeutics Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stem Cell Therapeutics Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective: To assess the neurological outcome in acute ischemic stroke patients
      treated with NTx™-265, when compared with patients given a placebo control.

      Secondary objective: To assess the safety and tolerability of NTx™-265 when given to acute
      ischemic stroke patients.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Anticipated">January 2009</completion_date>
  <primary_completion_date type="Anticipated">October 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Modified Rankin Score (mRS)</measure>
    <time_frame>Day 90</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>NIHSS response</measure>
    <time_frame>Day 90</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>NIHSS</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mRS</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barthel Index</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Action Research Arm Test</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gait Velocity Test</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Boston Naming Test</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Line Cancellation Test</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trails A &amp; B Test</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">134</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NTx™-265: rhCG, then rEPO</intervention_name>
    <description>rhCG 10,000 IU, SC, on Day 1, 3, and 5 of study participation, then
rEPO 30,000 IU, IV, on Day 7, 8, and 9 of study participation</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Ovidrel</other_name>
    <other_name>Eprex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline placebo</intervention_name>
    <description>Saline SC, on Day 1, 3, and 5 of study participation, then
Saline IV, on Day 7, 8, and 9 of study participation</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Sodium Chloride 0.9%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-85.

          -  NIHSS score 6-24 within 24-48 hours after stroke onset and enrolment.

          -  Stroke is ischemic in origin, supratentorial, and radiologically confirmed (CT scan or
             diagnostic MRI) prior to enrolment.

          -  Patient is 24-48 hours from time of stroke onset when the first dose of NTxTM-265
             therapy is administered. Time of onset is when symptoms began; for stroke that
             occurred during sleep, time of onset is when patient was last seen or was
             self-reported to be normal.

          -  Reasonable expectation of availability to receive the full 9 day NTxTM-265 course of
             therapy, and to be available for subsequent follow-up visits.

          -  Reasonable expectation that patient will receive standard post-stroke physical,
             occupational and speech therapy as indicated.

          -  Female patient is either:

               1. Not of childbearing potential, defined as postmenopausal for at least 1 year or
                  surgically sterile (bilateral oophorectomy or hysterectomy) or

               2. If of childbearing potential, agrees to use two of the following effective
                  separate forms of contraception throughout the study, up to and including the
                  follow-up visits:

                    -  Condoms, sponge, foams, jellies, diaphragm or intrauterine device,
                       contraceptives (e.g., implants, injectables, combined oral, etc) OR

                    -  A vasectomised partner OR

                    -  Abstinence

        Exclusion Criteria

          -  Patients presenting with lacunar, hemorrhagic and/or brain stem stroke.

          -  Patients who have received thrombolytic treatment with tPA following the index stroke.

          -  Patients classified as comatose, defined as a patient who required repeated
             stimulation to attend, or is obtunded and requires strong or painful stimulation to
             make movements (NIHSS 1A score must be &lt;2)

          -  Women who have tested positive for pregnancy, or are breast-feeding or are not using a
             highly effective method of birth control that can be maintained for the duration of
             the study.

          -  Serum hemoglobin &gt; 16 g/dL (males) or &gt; 14 g/dL (females); or platelet count &gt;
             400,000/mm3.

          -  Advanced liver,kidney, cardiac or pulmonary disease; the former will be operationally
             defined using NCI Toxicity Criteria (Grade 2 or higher)

          -  Serum bilirubin &gt; 1.5 x upper limit of normal (ULN).

          -  Alkaline phosphatase &gt; 2.5 x ULN.

          -  AST&gt;2.5xULN.

          -  ALT &gt; 2.5 x ULN.

          -  Creatinine &gt; 2.0 x ULN.

          -  Patients with known and documented transferrin saturation &lt; 20%.

          -  Patients with known and documented ferritin &lt; 100 ng/mL.

          -  Patients with known and documented elevated PSA levels, or a PSA level of ≥ 4 ng/mL at
             screening.

          -  Patients with a known or current history of abnormal hypercoagulability parameters ,
             including known cardiolipin/antiphospholipid antibody syndrome.

          -  Expected survival &lt; 1 year.

          -  Allergy or other contraindication to hCG including:

               1. Prior hypersensitivity to hCG preparations or one of their excipients.

               2. Primary ovarian failure.

               3. Uncontrolled thyroid or adrenal dysfunction.

               4. An uncontrolled organic intracranial lesion such as a pituitary tumor.

               5. Abnormal uterine bleeding of undetermined origin.

               6. Ovarian cyst or ovarian enlargement of undetermined origin.

               7. Sex hormone dependent tumors of the reproductive organs, accessory sex glands,
                  and breasts.

          -  Allergy or other contraindication to epoetin alfa:

               1. Who developed pure red cell aplasia following treatment with any erythropoiesis
                  regulating hormones

               2. With uncontrolled hypertension

               3. With known hypersensitivity to mammalian cell-derived products, albumin (human)
                  or any component of the product

               4. Who for any reason cannot receive adequate antithrombotic treatment

          -  A known diagnosis of cancer (except non-malignant skin cancer).

          -  Uncontrolled hypertension, defined in the context of acute stroke as blood pressure
             persistently above 220 mm Hg systolic or 120 mm Hg diastolic despite antihypertensive
             therapy.

          -  Use of either hCG or epoetin alfa within the previous 90 days.

          -  Any condition known to elevate hCG, active in the prior 24 months, e.g.,
             choriocarcinoma or germ cell tumor.

          -  Patients with a pre-stroke/pre-morbid modified Rankin Score (mRS) ≥ 2.

          -  Any patients living in a nursing home or supervised living center. Patients must be
             historically fully independent in all activities of daily living including banking,
             shopping, cooking, toileting, showering and dressing.

          -  Any other medical condition or degree of stroke such that, in the investigator's
             opinion, the patient should not be included in the trial.

          -  With the exception of the qualifying stroke, any other stroke within the previous 6
             months.

          -  Patients who cannot take anti-platelet therapy for the duration of the study.

          -  Patients who cannot take low molecular weight or unfractionated heparin during
             hospitalization.

          -  Pre-existing and active major psychiatric or other chronic neurological disease.

          -  Consume, on average, greater than 14 alcoholic drinks per week, or have a history of
             substance abuse or dependency within 12 months prior to the study.

          -  Currently participating in another investigational study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael D Hill, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Neurosciences, University of Calgary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven C Cramer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurology, University of Califonia, Irvine Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Clinical Neurosciences, Univeristy of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Walter Mackenzie Health Sciences Centre</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grey Nuns Community Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6L 5X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chinook Regional Hospital</name>
      <address>
        <city>Lethbridge</city>
        <state>Alberta</state>
        <zip>T1J 1W5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penticton Regional Hospital</name>
      <address>
        <city>Penticton</city>
        <state>British Columbia</state>
        <zip>V2A 3G6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vancouver Island Health Research Centre</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8R 1J8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brandon Regional Health Centre</name>
      <address>
        <city>Brandon</city>
        <state>Manitoba</state>
        <zip>R7A 2B3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 3A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McMaster Clinic</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trillium Health Centre</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5B 1B8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thunder Bay Regional Health Sciences Centre</name>
      <address>
        <city>Thunder Bay</city>
        <state>Ontario</state>
        <zip>P7B 6V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Neurology , Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Neurological Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Care Hospital</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krishna Institute of Medical Sciences</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Apollo Hospitals</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500033</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Nizam's Institute of Medical Science</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500082</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Max Super Speciality Hospital</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110017</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M S Ramaiah Memorial Hospital</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christian Medical College &amp; Hospital</name>
      <address>
        <city>Ludhiana</city>
        <state>Punjab</state>
        <zip>141008</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Christian Medical College</name>
      <address>
        <city>Vellore</city>
        <state>Tamilnadu</state>
        <zip>632004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AMRI Hospital</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, B.P.Poddar Hospital &amp; Medical Research Ltd</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700053</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>India</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2008</study_first_submitted>
  <study_first_submitted_qc>April 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2008</study_first_posted>
  <last_update_submitted>August 10, 2009</last_update_submitted>
  <last_update_submitted_qc>August 10, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2009</last_update_posted>
  <responsible_party>
    <name_title>Alan Moore / President &amp; Chief Executive Officer</name_title>
    <organization>Stem Cell Therapeutics Corp.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
    <mesh_term>Chorionic Gonadotropin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

